Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7247669 in Advanced and/or Metastatic Solid Tumors
NCT04140500Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2019
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, open-label trial of tobemstomig in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Roche. Primary endpoints: Dose-Limiting Toxicities, Adverse Events up to 24 months and 4 more. Started Nov 2019; status: active, not recruiting.
02
Drugs
tobemstomig
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04140500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04140500.